FDMT 4D Molecular Therapeutics Inc

Price (delayed)

$31.86

Market cap

$1.59B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.58

Enterprise value

$1.35B

4DMT is a clinical-stage company harnessing the power of directed evolution for targeted gene therapies. 4DMT seeks to unlock the full potential of gene therapy using its platform, Therapeutic Vector ...

Highlights
4D Molecular Therapeutics's EPS has increased by 22% YoY and by 5% from the previous quarter
The company's debt fell by 9% YoY and by 3.2% QoQ
The company's equity rose by 33% YoY but it fell by 7% QoQ
FDMT's quick ratio is down by 14% QoQ but it is up by 12% YoY
The gross profit has declined by 6% since the previous quarter
FDMT's revenue is down by 6% since the previous quarter

Key stats

What are the main financial stats of FDMT
Market
Shares outstanding
49.78M
Market cap
$1.59B
Enterprise value
$1.35B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
4.42
Price to sales (P/S)
60.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
65.22
Earnings
Revenue
$20.72M
EBIT
-$100.84M
EBITDA
-$95.09M
Free cash flow
-$78.56M
Per share
EPS
-$2.58
Free cash flow per share
-$2.01
Book value per share
$7.2
Revenue per share
$0.53
TBVPS
$8.69
Balance sheet
Total assets
$339.89M
Total liabilities
$32.06M
Debt
$14.67M
Equity
$307.83M
Working capital
$277.64M
Liquidity
Debt to equity
0.05
Current ratio
15.65
Quick ratio
15.21
Net debt/EBITDA
2.47
Margins
EBITDA margin
-458.9%
Gross margin
100%
Net margin
-486.6%
Operating margin
-544.6%
Efficiency
Return on assets
-31.1%
Return on equity
-34.1%
Return on invested capital
-88.2%
Return on capital employed
-31.4%
Return on sales
-486.6%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

FDMT stock price

How has the 4D Molecular Therapeutics stock price performed over time
Intraday
-11.18%
1 week
-5.74%
1 month
14.23%
1 year
90.55%
YTD
57.26%
QTD
57.26%

Financial performance

How have 4D Molecular Therapeutics's revenue and profit performed over time
Revenue
$20.72M
Gross profit
$20.72M
Operating income
-$112.87M
Net income
-$100.84M
Gross margin
100%
Net margin
-486.6%
The company's net margin has surged by 86% YoY but it fell by 12% QoQ
The operating margin has soared by 85% YoY but it has contracted by 14% from the previous quarter
The operating income is down by 8% QoQ and by 2.6% YoY
The company's net income rose by 6% YoY but it fell by 5% QoQ

Growth

What is 4D Molecular Therapeutics's growth rate over time

Valuation

What is 4D Molecular Therapeutics stock price valuation
P/E
N/A
P/B
4.42
P/S
60.16
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
65.22
4D Molecular Therapeutics's EPS has increased by 22% YoY and by 5% from the previous quarter
The stock's P/B is 101% above its last 4 quarters average of 2.2
The company's equity rose by 33% YoY but it fell by 7% QoQ
The P/S is 61% lower than the last 4 quarters average of 155.2
FDMT's revenue is down by 6% since the previous quarter

Efficiency

How efficient is 4D Molecular Therapeutics business performance
4D Molecular Therapeutics's ROS has soared by 86% YoY but it has decreased by 12% from the previous quarter
The return on invested capital has dropped by 70% year-on-year and by 33% since the previous quarter
The return on equity is up by 17% year-on-year
The ROA has grown by 15% YoY

Dividends

What is FDMT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for FDMT.

Financial health

How did 4D Molecular Therapeutics financials performed over time
4D Molecular Therapeutics's total assets has increased by 30% YoY but it has decreased by 6% from the previous quarter
FDMT's quick ratio is down by 14% QoQ but it is up by 12% YoY
The company's debt is 95% lower than its equity
The company's equity rose by 33% YoY but it fell by 7% QoQ
FDMT's debt to equity is down by 29% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.